Business
Presents data at XVIII WFN Wo
Presents data at XVIII WFN Wo.
About this update from Ixico Plc
[{"type":"text","content":"\n RNS Number : 0314E Phytopharm PLC 14 December 2009 \n \nPhytopharm to present data at XVIII WFN World Congress on Parkinson's Disease and Related Disorders in Miami\n\nGODMANCHESTER, Cambridgeshire, U.K. (14 December 2009) - Phytopharm plc (LSE: PYM) (\"Phytopharm\" or the \"Company\") announces that Dr Jonathan Brotchie will present data from a \"gold-standard\" non-clinical study of Cogane™, a promising novel oral treatment for Parkinson's disease, at the 50th WFN World Congress on Parkinson's Disease and Related Disorders, which is taking place in Miami from 13 - 16 December. \n\nThe outcome of this study, an overall 43% decrease in parkinsonian symptoms over 18 weeks administration of Cogane™, was first reported by Phytopharm on 14 October 2009 along with the results of a successful safety, tolerability and pharmacokinetic trial in healthy volunteers and patients with Parkinson's disease. \n\nDr Brotchie, a senior scientist at Toronto Western Hospital, who conducted the trials, is a recognised expert in the field of Parkinson's disease and runs one of the world's premier research laboratories for the identification of novel treatments, diagnostics and cures for Parkinson's disease and related disorders. \n\n-Ends-\n\nNotes to Editors\n\nAbout Phytopharm\nPhytopharm is focused on the development of its pharmaceutical programmes and has a residual portfolio of functional foods. The Company's products are developed predominantly from medicinal plants, thereby reducing the development risk of a product. The Company has focused its research and development activities on areas of high unmet health needs to deliver cures and relieve suffering for longer healthier lives. As a virtual company, the Company's business model is centered on a lean cash burn with all laboratory, manufacturing and clinical work outsourced to specialists, while core competencies such as strategy and management are maintained in-house. Close collaboration with charitable organisations enhances the Company's interaction with scientists and clinicians, who lead and develop expert opinion. Cash grants from them accelerate the Company's development programmes, thereby increasing their value.\n\nAbout Cogane™\nCogane™ is a novel small molecule, orally bioavailable neurotrophic factor inducer tha...